ArticleInternational journal of immunopathology and pharmacology
Lymphocyte subsets as a predictor of severity and prognosis in COVID-19 patients.
Article in International journal of immunopathology and pharmacology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 11 citations in OpenAlex.
- Decreased CD3 + CD4+ T lymphocyte count predicts 28-day all-cause mortality in severe AECOPD patients admitted to the ICU: a retrospective cohort study.Scientific reports · 2026Article
- Trend in Hospital Admissions for Cardiovascular Diseases (CVDs) Before and During the Coronavirus Disease 2019 (COVID-19) Pandemic: A Retrospective Analysis From a Sub-Urban Area in Sub-Saharan Africa.Health science reports · 2026Article
- Inflammation and iron metabolism dysregulation as hallmarks of COVID-19 severity.Frontiers in immunology · 2026Observational
- Observational
- Development and validation of nomogram models for severe and fatal COVID-19.Scientific reports · 2024Article
- Angiotensin-(1-7) decreases inflammation and lung damage caused by betacoronavirus infection in mice.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2024Article
- Lymphocyte and neutrophil count combined with intestinal bacteria abundance predict the severity of COVID-19.Microbiology spectrum · 2024Article
- Predictive Value of IL-6 and Lymphocyte Subsets for Death in Children With Influenza-Associated Encephalopathy A Retrospective Study.Mediators of inflammation · 2024Article
- Resumption of Intravenous Anti-Cancer Therapy in Breast Cancer: A Real-World Experience During the SARS-CoV-2 Pandemic.Cancer management and research · 2024Article
- How immune breakthroughs could slow disease progression and improve prognosis in COVID-19 patients: a retrospective study.Frontiers in immunology · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCoronavirus disease 2019 (COVID-19) had become a worldwide health threat. Early prediction of the severity of COVID-19 patients was important for reducing death rate and controlling this disease. METHODS AND MATERIALS: A total of 301 patients confirmed with COVID-19 in Wuhan from 8 February to 10 April 2020 were included. Clinical data were collected and analyzed. Diagnostic and prognostic utility of blood cell counts and lymphocyte subsets in COVID-19 patients were investigated. The receiver operator characteristic curve (ROC) was used in discriminating the mild and severe/critical cases.
resultsThere were difference in blood cell counts and lymphocyte subsets among mild, severe and critical patients, which were also influenced by comorbidities and duration of disease. The area under the ROC of lymphocyte, CD3
conclusionBlood cell counts and lymphocyte subsets correlated with severity of COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.